In last trading session, Regenxbio Inc (NASDAQ:RGNX) saw 0.63 million shares changing hands with its beta currently measuring 1.33. Company’s recent per share price level of $7.27 trading at -$0.09 or -1.22% at ring of the bell on the day assigns it a market valuation of $360.19M. That closing price of RGNX’s stock is at a discount of -296.15% from its 52-week high price of $28.80 and is indicating a premium of 9.77% from its 52-week low price of $6.56.

For Regenxbio Inc (RGNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.45. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.08 in the current quarter.

Regenxbio Inc (NASDAQ:RGNX) trade information

Upright in the red during last session for losing -1.22%, in the last five days RGNX remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $7.27 price level, adding 6.68% to its value on the day. Regenxbio Inc’s shares saw a change of -5.95% in year-to-date performance and have moved -0.68% in past 5-day. Regenxbio Inc (NASDAQ:RGNX) showed a performance of -7.39% in past 30-days.

Wall Street analysts have assigned a consensus price target of 26 to the stock, which implies a rise of 72.04% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 39. It follows that stock’s current price would drop -147.59% in reaching the projected high whereas dropping to the targeted low would mean a loss of -147.59% for stock’s current value.

Regenxbio Inc (RGNX) estimates and forecasts

This year revenue growth is estimated to fall -3.47% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 23.7M for the same. And 5 analysts are in estimates of company making revenue of 20.51M in the next quarter. Company posted 22.21M and 15.62M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around 21.49% while estimates for its earnings growth in next 5 years are of 26.49%.

Regenxbio Inc (NASDAQ:RGNX)’s Major holders

BLACKROCK INC. is the top institutional holder at RGNX for having 8.61 million shares of worth $100.73 million. And as of 2024-06-30, it was holding 18.8252 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.11 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.1818 of outstanding shares, having a total worth of $59.83 million.

On the other hand, iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.94 shares of worth $21.39 million or 5.94% of the total outstanding shares. The later fund manager was in possession of 1.4 shares on Sep 30, 2024 , making its stake of worth around $10.18 million in the company or a holder of 2.83% of company’s stock.